519 related articles for article (PubMed ID: 16380499)
1. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
4. Transgenic expression of a mutated cyclin-dependent kinase 4 (CDK4/R24C) in pancreatic beta-cells prevents progression of diabetes in db/db mice.
Miyawaki K; Inoue H; Keshavarz P; Mizuta K; Sato A; Sakamoto Y; Moritani M; Kunika K; Tanahashi T; Itakura M
Diabetes Res Clin Pract; 2008 Oct; 82(1):33-41. PubMed ID: 18678431
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of muraglitazar in type 2 diabetic subjects.
Fernandez M; Gastaldelli A; Triplitt C; Hardies J; Casolaro A; Petz R; Tantiwong P; Musi N; Cersosimo E; Ferrannini E; DeFronzo RA
Diabetes Obes Metab; 2011 Oct; 13(10):893-902. PubMed ID: 21615671
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
[TBL] [Abstract][Full Text] [Related]
8. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Coletta DK; Fernandez M; Cersosimo E; Gastaldelli A; Musi N; DeFronzo RA
Diabet Med; 2015 May; 32(5):657-64. PubMed ID: 25484175
[TBL] [Abstract][Full Text] [Related]
9. The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
Tozzo E; Ponticiello R; Swartz J; Farrelly D; Zebo R; Welzel G; Egan D; Kunselman L; Peters A; Gu L; French M; Chen S; Devasthale P; Janovitz E; Staal A; Harrity T; Belder R; Cheng PT; Whaley J; Taylor S; Hariharan N
J Pharmacol Exp Ther; 2007 Apr; 321(1):107-15. PubMed ID: 17259449
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
11. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
12. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
13. Muraglitazar (Bristol-Myers Squibb/Merck).
Barlocco D
Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
[TBL] [Abstract][Full Text] [Related]
14. Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice.
Mohapatra J; Sharma M; Singh S; Chatterjee A; Swain P; Balaraman R; Patel PR; Jain MR
Pharmacology; 2009; 84(4):203-10. PubMed ID: 19738399
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.
Verreth W; Ganame J; Mertens A; Bernar H; Herregods MC; Holvoet P
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):922-8. PubMed ID: 16456093
[TBL] [Abstract][Full Text] [Related]
16. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
17. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF
Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028
[TBL] [Abstract][Full Text] [Related]
18. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
19. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
